Geron submits NDA for imetelstat in lower risk MDS; Q2 cash $400.2M

GERON CORP

Submitted first NDA for a telomerase inhibitor (imetelstat) to FDA for lower risk MDS in June 2023.
Cash, equivalents and securities of $400.2M as of June 30; expects to fund operations through end of 2025.
Reaffirmed FY2023 GAAP total expense guidance of $210M–$220M; non-GAAP $200M–$210M.
IMpactMF Phase 3 trial in myelofibrosis enrolled >40%; interim analysis expected H1 2025.
Appointed Scott Samuels as EVP, Chief Legal Officer and Corporate Secretary effective August 1, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GERON CORP reported the three and six months ended June 30, 2023 results: revenue $29,000 and $50,000, respectively.

Period: the three and six months ended June 30, 2023
Revenue: $29,000 and $50,000, respectively
Result: reported results

Exact text from the filing

to fund its projected operating requirements through the end of 2025. Second Quarter 2023 Financial Results Revenues for the three and six months ended June 30, 2023, were $29,000 and $50,000, respectively, compared to $73,000 and $196,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of cell-based

View on SEC.gov

Browse all earnings releases →

GERON CORP filing history →

Source: SEC EDGAR

accession 0000950170-23-038061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.